Oakwood Labs will be exhibiting at Booth #31 and speaking at the upcoming 2024 PODD Conference taking place from October 28-29 in Boston. If you would like to learn more about the event and register to attend, please visit the following link: https://poddconference.com/

Company Overview

Oakwood Labs is a global leader in sustained release drug delivery. We support all phases of long acting injectable development from initial feasibility studies through FDA-approved clinical and commercial supply. Oakwood has 27 years of drug encapsulation experience using Chroniject™, our patented microsphere-based technology. Chroniject™ provides the ability to control particle size, customize release durations from weeks to years, and minimize residual solvents to achieve critical quality attributes.

Listen to Oakwood’s presentation during Day 1 on our Chroniject Technology: A Solution to Long Acting Injectable Formulation and Scale-Up Challenges

Colin Spencer, a project manager working within our technology transfer team will be presenting during Day 1 (Monday, October 28^th) of the conference within the Track 1A: Injectable Formulations & Technologies at 2:30pm.

The presentation will include the following key points:

• Oakwood’s Chroniject technology provides a tunable long-acting injectable platform for a wide array of molecules and applications. Efficacious release profiles have been generated from as fast as two days to as long as one year.
• Oakwood’s Chroniject technology provides the platform for scale-up of the formulation process, allowing for the critical quality attributes of the long-acting injectable formulations to be maintained from initial feasibility batch sizes in the gram-scale to clinical and commercial batch sizes in the kilogram-scale.

Stop by Oakwood Lab’s Booth #31 to meet our team and learn more about how we can assist in the following areas:

• Long Acting Injectable Patented Technology (CDMO Services)
  • Feasibility assessments
  • Scale-up and optimization of lead formulation
  • Manufacturing, characterization, and stability of R&D toxicology batches
  • GMP Clinical trial manufacturing (Phase I, II, III)
  • GMP Commercial manufacturing

• Contract Manufacturing (CMO Services)
  • Technology Transfer
  • GMP Registration and Validation batches
  • Aseptic GMP commercial batch manufacturing
  • ICH compliant stability testing

Contact Us for More Information

PODD 2024 conference covers a wide range of topics, and we are happy to contribute to the event! If you aren’t able to attend, but still want to learn more about Oakwood Labs or what you missed at the conference, contact us today!

We look forward to discussing our technology and more.

• Author
• Recent Posts

Mark Ilhan

Mark Ilhan joined Oakwood Labs in 2013. Over the last 7 years he has worked to establish and maintain relationships with a variety of global pharmaceutical clients. Primary activities include representing Oakwood at global conferences with the scientific team, creating drug development proposals, and strategic marketing. His expertise is in Business Development and Project Management. He received a Bachelor’s degree in Management and Finance from Case Western University, and an MBA from Cleveland State University.

Latest posts by Mark Ilhan (see all)

• Opioid Use Disorder: Developing Long-Acting Injectables for Treatment - November 5, 2024
• Listen to Oakwood Labs Present Chroniject Technology at the 2024 PODD Conference - October 17, 2024
• Find Oakwood Labs at the 2024 AAPS PharmSci 360 - October 9, 2024